• Corpus ID: 19306008

High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?

  title={High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?},
  author={Maria Khan and Kamali Kamran},
  journal={JPMA. The Journal of the Pakistan Medical Association},
  volume={60 6},
Cochrane review on ‘Statins for the treatment of dementia’
This review aimed to assess the clinical efficacy and tolerability of statins in the treatment of dementia.
Pharmacotherapy prior to and in acute haemorrhagic stroke. The use of pharmacotherapy and drugs associated outcomes in real-world practice - findings from the Polish Hospital Stroke Registry.
The analysis of pharmacotherapy showed low preventive use of hypotensive agents in hypertensive patients, high consumption of antibiotics and still overuse of vasoactive or neuroprotective compounds in acute haemorrhagic stroke, which reflects the need to improved quality and evidence-based clinical practice.
Is There Enough Evidence for Aspirin in High-Risk Groups?
Aspirin prophylaxis would seem to be of particular value as a complement to colorectal cancer screening, and should be evaluated in relation to both vascular disease and cancer reduction together.
Is There an Optimal Management Regimen for Transient Ischaemic Attack Patients to Best Prevent Stroke
Although many patients with acute ischemic stroke have repeatedly been demonstrated to benefit from this advanced concept of ‘time is brain’ and ‘stroke is an emergency’, those patients with rapid, spontaneous recovery after onset of symptoms have still been investigated less sufficiently.
Withdrawal from Statins: Implications for Secondary Stroke Prevention and Acute Treatment
Patients with previous statin treatment before suffering an ischemic stroke have better functional outcome at 3 months, compared with those without previous treatment with statins, despite similar stroke severity at admission, and data obtained from clinical trials in secondary prevention of coronary heart disease show that statintreatment reduces stroke risk to 30%.


High-dose atorvastatin after stroke or transient ischemic attack.
  • J. Farmer
  • Medicine
    Current atherosclerosis reports
  • 2007